Results 101 to 110 of about 2,329 (147)

Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. [PDF]

Inflamm Bowel Dis
Faye AS, Rubin DT, Siegel CA, Long MD, Khan N, Danese S, Irving PM, Cross RK, Blumenstein I, Armuzzi A, Horst SN, Dignass A, Kobayashi T, Lawlor G, Krakovich A, Petersen A, Liu Z, Wang D, Jain A, Ananthakrishnan AN, Sabino J.   +20 more
europepmc   +1 more source

Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms. [PDF]

Front Gastroenterol (Lausanne)
Chater F, Butler TD, Limdi JK.
europepmc   +1 more source

Real-world experience of ozanimod in adults with multiple sclerosis. [PDF]

Neurodegener Dis Manag
Cooperrider J, Lambe J, Chu M, Du M, Reardon J, Chaudry B, Thorpe A, Hersh CM, Conway D.   +8 more
europepmc   +1 more source

Comment on "Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort". [PDF]

J Gastroenterol Hepatol
Li HS, Yao YH, Li SN, Liu L.
europepmc   +1 more source

Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. [PDF]

Inflamm Bowel Dis
Yarur A, Irving P, Siegmund B, Dubinsky MC, Ananthakrishnan AN, Regueiro M, Ungaro RC, Ritter T, Nakase H, Liu Z, Mehra D, Osterman MT, Jain A, Rubin DT, Hibi T.   +14 more
europepmc   +1 more source

Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review. [PDF]

J Neurol
Zheng Y, Bhalala OG, Chin KS, Watson R, Yassi N.   +4 more
europepmc   +1 more source

Effects of Sphingosine 1-phosphate Modulators on Central Remyelination: A Systematic Review of Animal Models. [PDF]

Cell Mol Neurobiol
Vu H, George N, Xiao J.
europepmc   +1 more source

Predictors of high- versus low-intensity first-line multiple sclerosis treatments. [PDF]

Mult Scler J Exp Transl Clin
Chevalier AVG, Murray K, Lin A, Kerber K, Burke JF, Gyang TV.   +5 more
europepmc   +1 more source

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial. [PDF]

Mult Scler
Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Krakovich A, Cheng CY, Riolo JV, Pachai C, Thorpe A, DeBoer E, Kappos L, Cohen JA, Cree BA.   +17 more
europepmc   +1 more source

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries. [PDF]

Paediatr Drugs
Gupte D, Suthar NR, MacDonald JK, Le J, Colman RJ, Feagan BG, Cheng C, Hanzel J, Ma C, Jairath V, Crowley E.   +10 more
europepmc   +1 more source